The anti-obesity potential of sigmoidin A

Figures & data

Figure 1.  Structures of eriodictyol (ERD) and sigmoidin A (SGN).

Table 1.  Antilipase and anti-α-glucosidase inhibitory effects of test compounds.

	Pancreatic lipase inhibition (IC50)*	α-Glucosidase inhibition (IC50)*
Eriodictyol	134 ± 19.39 µM	57.5 ± 13.15 µM
Sigmoidin A	4.5 ± 0.87 µM	62.5 ± 9.47 µM
Orlistat	0.3 ± 0.04 µM	–
Acarbose	–	190.6 ± 16.05 µM

*Data are mean and SEM values obtained from 4 to 6 separate experiments.

Figure 2.  Anti-lipase activity profile of eriodictyol (ERD), sigmoidin (SGN) and orlistat. Data from a representative result shows mean and SEM values (n = 4).